Edition:
United Kingdom

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

16.83USD
15 Dec 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$16.83
Open
$16.80
Day's High
$16.97
Day's Low
$16.50
Volume
1,042,523
Avg. Vol
73,053
52-wk High
$20.43
52-wk Low
$11.25

Latest Key Developments (Source: Significant Developments)

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle
Friday, 1 Dec 2017 

Athenex Inc ::ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE.ATHENEX INC - ‍COMPANY WILL COMMENCE AN EXECUTIVE SEARCH TO IDENTIFY A SUITABLE REPLACEMENT FOR CFO ROLE​.ATHENEX INC - ‍RIEHLE WILL CONTINUE TO SERVE AS AN ADVISOR TO COMPANY​.  Full Article

Athenex announces Q3 revenue of $14 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Athenex Inc :Athenex, Inc. Announces third quarter 2017 results.Q3 revenue rose 149 percent to $14 million.Sees FY 2017 revenue $33 million to $35 million.Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​.FY2017 revenue view $32.3 million -- Thomson Reuters I/B/E/S.Athenex Inc - Sees launch of 4 additional products in Athenex Pharmaceutical division & 2 products in Athenex Pharma solutions in 4Q'17​.  Full Article

Rand Capital reports NAV of $5.00/shr at June 30, 2017
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Rand Capital Corp :Rand Capital announces second quarter 2017 results.Rand Capital Corp - reported $5.00 net asset value per share at June 30, 2017, compared with $5.10 at March 31, 2017​.Rand Capital Corp qtrly ‍basic and diluted net decrease in net assets from operations per share $0.10​.  Full Article

BRIEF-Athenex Inc ‍Initiates Oral Eribulin Investigational New Drug Development Program For Oncology Indications​

* ATHENEX INC - ‍INITIATION OF AN ORAL ERIBULIN INVESTIGATIONAL NEW DRUG DEVELOPMENT PROGRAM FOR ONCOLOGY INDICATIONS​ Source text for Eikon: Further company coverage: